The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways.

MLA

Boileau C, et al. “The Peroxisome Proliferator-Activated Receptor Gamma Agonist Pioglitazone Reduces the Development of Cartilage Lesions in an Experimental Dog Model of Osteoarthritis: In Vivo Protective Effects Mediated through the Inhibition of Key Signaling and Catabolic Pathways.” Arthritis & Rheumatism, vol. 56, no. 7, July 2007, pp. 2288–98. EBSCOhost, https://doi.org/10.1002/art.22726.

APA

Boileau C, Martel-Pelletier J, Fahmi H, Mineau F, Boily M, & Pelletier JP. (2007). The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Arthritis & Rheumatism, 56(7), 2288–2298. https://doi.org/10.1002/art.22726

Chicago

Boileau C, Martel-Pelletier J, Fahmi H, Mineau F, Boily M, and Pelletier JP. 2007. “The Peroxisome Proliferator-Activated Receptor Gamma Agonist Pioglitazone Reduces the Development of Cartilage Lesions in an Experimental Dog Model of Osteoarthritis: In Vivo Protective Effects Mediated through the Inhibition of Key Signaling and Catabolic Pathways.” Arthritis & Rheumatism 56 (7): 2288–98. doi:10.1002/art.22726.